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Abstract
Background Diagnostic biomarkers have multiple appli-
cations along the care process and have a large potential in
optimizing treatment decisions. However, many diagnostic
biomarkers struggle to gain market access and obtain
appropriate coverage because of a lack of evidence on their
health economic impact.
Objectives The aim was to review the (methodological)
characteristics of recent economic evaluations on diag-
nostic biomarkers and examine whether these studies dealt
with specific issues such as different payer perspectives,
preference heterogeneity, and multiple applications in
subpopulations.
Methods The PubMed database and the National Health
Service Economic Evaluation Database were searched. Full
economic evaluations published after 2009 assessing
diagnostic biomarkers for the main non-communicable
diseases in middle-income or high-income countries were
considered eligible. Empirical and methodological study
characteristics were summarized, as was the handling of
specific issues related to the economic evaluation of per-
sonalized medicine.
Results Thirty-three economic evaluations were included,
of which 25 were model-based analyses. The number of
strategies compared ranged from two to 17 per study, and
was especially large in studies assessing genetic testing in
patients and their relatives. Cost-effectiveness results were
most sensitive to test accuracy and costs of the biomarker
(N = 7), the relative risk of an event (N = 4), and the
proportion of people accepting genetic testing (N = 2).
One study incorporated patient preferences, and none of the
studies considered different payer perspectives, cost shar-
ing arrangements or variable opportunity costs due to
population density variability.
Conclusions Published health economic evaluations of
biomarkers used for diagnosing, staging diseases, and
guiding treatment selection are characterized by a large
number of comparators to model the potential clinical
applications and to determine their value. Assessing out-
comes beyond health as well as specific issues, such as
different payer perspectives and patient preferences, is
crucial to fully capture the potential health economic
impact of diagnostic biomarkers and to inform value-based
reimbursement.
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Key Points for Decision Makers
Evidence about the health economic outcomes of a
diagnostic test is often lacking and has been
mentioned as a common reason for diagnostics
failing to obtain appropriate coverage.
Evaluating the cost effectiveness of diagnostic
biomarkers is challenging because diagnostics
themselves do not influence long-term outcomes
directly, but rather impact on therapeutic decisions
and the subsequent care process.
Economic evaluations on diagnostic biomarkers
typically require comprehensive models to deal with
all possible test–treatment combinations in various
populations to assess their value in terms of health
economic outcomes.
More effort should be made to align the choice of
health economic evaluation designs and outcomes
with the actual information needs of the various
public and private payers and care provider decision
makers.
Incorporating the results of non-health outcomes and
patient preferences and improving the evidence base
of other input parameters is crucial to fully capture
the potential value of diagnostic biomarkers.
1 Background
The role and the potential value of biomarkers has received
increasing attention over the last 2 decades [1]. Biomarkers
represent a wide variety of technologies that are used in
various stages of the disease process [2]. For example, they
may indicate surrogate and clinical endpoints in order to
predict clinical benefit and to monitor patients during and
after treatment. Biomarkers are also used in earlier stages
of the disease process, such as biomarkers that help in early
disease detection, biomarkers for staging a disease, and
companion diagnostics that are used to guide the selection
of therapeutic strategies. As such, a biomarker is defined as
‘‘an indicator of a normal biological process, a pathogenic
process or a pharmacologic response to a therapeutic
intervention’’ [3]. Due to their various applications,
biomarkers have a large potential for optimizing the ther-
apeutic approach or the timing of treatment [4]. This
review focuses on biomarkers for diagnosing, staging, and
guiding the selection of therapeutic strategies for non-
communicable diseases since the number of research
activities is rapidly increasing in this field [5]. Despite the
large number of diagnostic biomarkers becoming available,
only a small number are implemented in the clinical set-
ting, because of a lack of robust evidence supporting their
clinical utility or costs and because of the tension between
technical possibilities and resource constraints [6].
To prioritize between competing innovations, decision
makers require information about the health economic
impact of interventions, which is assessed by their benefits
and costs. In this context, payers have become more critical
and put more weight on examining the clinical utility of a
diagnostic test, including biomarkers, when making cov-
erage decisions [7]. The clinical utility is assessed by the
link between the test accuracy of a diagnostic test and the
associated health outcomes, and provides insight into the
benefits of diagnostics [8]. The importance of analyzing the
health impact of diagnostics is emphasized by Cohen et al.
[9], who concluded from a stakeholder analysis that the
cost of the biomarker is not as important for implementa-
tion as is the biomarker impact on the longer-term health
outcomes. When examining the health impact of a diag-
nostic test, patient and societal outcomes are considered to
be the most important outcome measures [10]. Patient
outcomes include the effects on morbidity, mortality, and
quality-adjusted life-years (QALYs), and societal out-
comes include cost effectiveness and net benefit from a
societal perspective [10]. However, evidence about these
health and economic outcomes of a diagnostic test is often
lacking and has been mentioned as a common reason for
failing to obtain appropriate coverage [11].
Evaluating the cost effectiveness of diagnostic
biomarkers is challenging because diagnostics themselves
do not influence long-term outcomes directly, but rather
impact the subsequent care process [12], which may or may
not be very effective. In examining the effectiveness of a
diagnostic biomarker, one needs to take into account (1)
the accuracy of the diagnostic test; (2) the impact of the
diagnostic on therapeutic decisions; and (3) the effective-
ness of the therapies selected [9, 13]. Another issue in
evaluating the health economic impact of a diagnostic
biomarker is the choice of its comparators. The number of
comparators can become (very) large because diagnostic
biomarkers are often combined with other (biomarker)
tests, resulting in an unwieldy number of realistic test
strategies. It is not yet clear how economic evaluations on
diagnostic biomarkers handle these methodological chal-
lenges and how economic evaluations of diagnostics are
(and should be) designed in this regard. The primary
objective of this study is to systematically review the
current literature on (methodological) characteristics of
cost-effectiveness evaluations of diagnostic biomarkers.
The secondary aim is to explore to what extent studies deal
52 M. Oosterhoff et al.
with a range of specific issues related to the economic
evaluation of diagnostic-based personalized medicine, such
as different payer perspectives, preference heterogeneity,
and multiple applications in subpopulations.
2 Methods
2.1 Search Strategy
A systematic literature search was performed in PubMed
and the National Health Service Economic Evaluation
Database (NHS EED) (until 5 February 2015) to identify the
most relevant published economic evaluations on diagnos-
tic biomarkers [14]. In both databases, free text words and
MeSH terms related to ‘‘biomarkers’’ and ‘‘diagnosis’’ were
combined (for full search queries see ‘‘Appendix’’). The
search in the PubMed database was complemented by the
relevant economic terms ‘‘cost-effectiveness’’ and ‘‘cost-
benefit analysis’’ (MeSH terms) from the sensitivity filter of
the Canadian Agency for Drugs and Technologies in Health
(CADTH) [15]. The searches were refined to papers pub-
lished in the English language from 2010 onwards to limit
the scope of this review to the most recent and state of the
art economic evaluations; hence, we considered a 5-year
retrospective horizon to be sufficient.
2.2 Study Selection
After identification of publications by the electronic sear-
ches, duplicate records were removed. Selection of papers
was based on the following eligibility criteria:
1. Patients: the intervention is being applied to human
subjects for diagnosis of one the main five non-
communicable diseases, being cardiovascular or cir-
culatory diseases, cancer, chronic respiratory diseases,
diabetes, and intermediate risk factors associated with
obesity [16].
2. Intervention: a diagnostic biomarker for the aforemen-
tioned diseases. Diagnostic biomarkers included risk
biomarkers for diagnosis and staging of diseases, and
companion diagnostics, which are defined as diagnos-
tic tools to guide treatment. Universal screening tools,
triage procedures, and severity, or progression analy-
ses were excluded.
3. Study type: a health economic evaluation is reported,
including methods, input data, and results, being a
model or trial-based cost-minimization (CMA), cost-
effectiveness (CEA), cost-utility (CUA), or cost-ben-
efit analysis (CBA). Publications merely reporting on
methodological issues, reviews, or comment letters
and editorials were excluded.
4. Setting: the intervention is evaluated in a country
defined as an upper-middle-income or high-income
economy by the World Bank [17].
Papers were first screened on title and abstract and were
excluded when one or more of the eligibility criteria were
not met. Subsequently, two reviewers (LS and MO) inde-
pendently assessed the remaining full texts to make a final
decision on inclusion for this review. Dissimilarities
between the reviewers were resolved by discussion.
2.3 Data Extraction
Data extraction of empirical and methodological study
characteristics was done using an adapted version of the
format reported by Pham et al. [2] and the CHEERS
statement [18]. The items reflected various study charac-
teristics, including the decision problem, the target popu-
lation and target audience, the evaluated biomarkers,
methodological aspects such as the model type and per-
spective, and the presence of uncertainty analyses. Sec-
ondly, it was assessed whether studies handled a number of
specific issues that were previously described by Husereau
et al. [19] as being of particular importance to the eco-
nomic evaluations of personalized medicine. These include
the presence of variable framing of research questions, the
evaluation of multiple subpopulations or strategies, testing
the sensitivity of effects with regard to compliance, pref-
erence heterogeneity, variable opportunity costs, and the
inclusion of cost-sharing arrangements. Two reviewers
(MO and MVDM) independently performed data extrac-
tion and resolved any dissimilarity by discussion.
3 Results
3.1 Study Selection
The literature search located 319 publications in the
PubMed and NHS EED databases, and two papers were
identified through hand-searching. A total of 39 duplicates
were removed, resulting in 282 unique papers. After
screening titles against the eligibility criteria, 159 papers
were selected for abstract and full-text examination. Of
these, 68 articles were excluded as they did not describe a
health economic evaluation. Another 42 papers were
excluded as these examined diagnostic biomarkers for
other than the main disease groups we focused on (cancer,
obesity, diabetes, cardiovascular, and respiratory diseases),
and eight papers were excluded as they assessed
biomarkers for universal screening or examined a total
triage procedure. Furthermore, eight articles were excluded
as they did not apply to middle- or high-income countries.
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A final set of 33 economic evaluations on diagnostic
biomarkers was included in this review (Fig. 1).
3.2 General Study Characteristics
Table 1 presents an overview of the general study charac-
teristics. Most health economic evaluations considered
biomarkers for confirming a diagnosis (N = 16) [20–35]
and some for staging a disease (N = 4) [36–39]. Genetic
testing was employed for treatment selection in patients
(N = 7) [40–46] or to test for a familial disease in patients
and their relatives (N = 6) [47–52]. Biomarkers were
applied to diagnose several types of cancer (N = 23) [20,
21, 24–30, 32–40, 44–48], cardiovascular/circulatory dis-
eases (N = 9) [22, 23, 31, 41, 43, 49–52], and respiratory
disease (N = 1) [42]. Economic evaluations were most
often performed in colorectal cancer and evaluated genetic
testing strategies like testing of BRAF and KRAS genetic
mutations. In contrast to the evaluations on colorectal
cancer which assessed genetic testing techniques, evalua-
tions on diagnostic biomarkers for lung and thyroid cancer
assessed techniques for needle aspiration and pre/intra-op-
erative molecular classification. In the field of cardiovas-
cular diseases, economic evaluations most often assessed
biomarkers that were primarily used for diagnosis in
patients (i.e., troponin for diagnosing myocardial infarc-
tion). The number of strategies that were assessed differed
between studies and ranged from two to 17 strategies
(median: three strategies). Fourteen studies reported a sin-
gle comparison of two strategies (N = 14) [21, 23, 26, 27,
30–32, 34, 36–39, 42, 44], i.e., an evaluation of a biomarker
strategy compared with no biomarker (N = 6) [21, 30, 31,
34, 36, 42] or a head to-head comparison of two specific
biomarkers (N = 8) [23, 26, 27, 32, 37–39, 44].
The maximum number of comparisons was 16 (N = 1),
in a study where 17 strategies were constructed on the basis
of clinical criteria, prediction algorithms, tumor testing,
and upfront germline mutation testing [47]. Economic
evaluations that assessed methods for genetic testing of a
disease in patients and their relatives defined and compared
more strategies than did evaluations on tests for diagnosing
and staging a disease in patients (mean of N = 6 vs. N = 3
and N = 2 strategies, respectively). About half of the
studies explicitly mentioned an aim to inform national
decision makers (N = 13) [25, 26, 28, 29, 38, 40–43, 46–
48, 51] or clinicians (N = 3) [31, 32, 39]. For the
remaining publications, the target audience was not clearly
stated (N = 17).
Fig. 1 Flow diagram of paper selection process. NHS EED National Health Service Economic Evaluation Database
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3.3 Methodological Characteristics
Table 2 displays a summary of the methodological char-
acteristics of the studies.
3.4 Type of Health Economic Evaluation
Most studies were model-based cost-effectiveness evalua-
tions (N = 25) [20, 22, 26–29, 31–35, 38–41, 43–52]. The
majority of these studies were CUA (N = 20) reporting the
incremental costs per QALY only (N = 11) [22, 23, 27, 31,
35, 38, 41, 43, 44, 49, 51] or the incremental costs per
QALY in combination with a cost-effectiveness estimate
such as costs per life-year gained (N = 7) [26, 28, 42, 45,
46, 48, 50]. Verry et al. [39] reported the incremental costs
and incremental QALYs, but not the incremental cost-
utility ratio, and Steinfort et al. [32] reported incremental
costs per QALY and cost savings. Nine studies performed a
CEA, of which two were trial based [25, 30], and reported
the incremental costs per life-year gained (N = 5) [29, 33,
40, 47, 52], the incremental costs per additional case
detected (N = 3) [25, 30, 34], or the incremental costs per
extra patient surviving at 5 years (N = 1) [20]. Eight trial-
based studies were identified, containing two CUAs [23, 42]
and two CEAs [25, 30]. The remaining four trial-based
studies presented incremental costs only and were classified
as CMAs [21, 24, 36, 37]. In two of these studies, evidence
was provided to support the equivalence of effects between
the intervention and its comparator(s) [24, 37].
3.5 Perspective and Time Horizon of the Analysis
Cost effectiveness was mostly assessed from a healthcare
system perspective (N = 15) [20, 22, 23, 25, 31, 33, 38–40,
42–44, 48, 49, 51], while some other studies adopted a
hospital perspective (N = 7) [21, 24, 30, 32, 34, 36, 52], a
third party payer perspective (N = 5) [26, 27, 41, 46, 47],
or limited the perspective to that of the operating room
(N = 1) [37]. Five studies adopted a societal perspective
[28, 29, 35, 45, 50], of which three studies presented the
productivity losses that were included [28, 35, 45].
The four studies that were classified as CMAs were trial-
based evaluations and incorporated both a short time
horizon (duration of diagnostic process or of hospital stay)
and adopted a local (hospital) perspective. Looking at
CEAs, the time horizon varied substantially. Three studies
used a time horizon capturing the duration of the diagnostic
process or the duration of hospital stay [25, 30, 34], whilst
there were also four studies that incorporated a lifetime
horizon [29, 33, 34, 47]. The majority of CUAs used a
lifetime horizon (N = 10) [22, 26–28, 31, 35, 43, 48, 49,
51] and adopted a healthcare system perspective (N = 11)
[22, 23, 31, 38, 39, 42–44, 48, 49, 51]. Only one CUA used
a hospital system perspective [32]. The time horizon in
model-based studies ranged from the duration of the
diagnostic process (N = 2) [32, 34] to a lifetime horizon
(N = 14) [22, 26–29, 31, 33, 35, 43, 47–49, 51, 52].
Panattoni et al. [43] incorporated both a short-term and
long-term (lifetime) horizon to distinguish direct effects
from long-term health economic outcomes.
3.6 Decision Model
Most model-based evaluations did contain a Markov model
to link the direct effects of biomarkers to long-term costs
and effects (N = 19) [26–29, 33, 35, 38–41, 43–47, 49–
52]. Nine of these studies used a decision tree to capture
the differences in accuracy of diagnostic strategies (sensi-
tivity/specificity) on (changes in) treatment recommenda-
tion, and fed this into a Markov model to estimate the
effects on resource use and health outcomes associated
with the recommended treatment(s) [26, 27, 41, 43, 47, 49–
52]. Nine other economic evaluations used a decision tree
only for modeling outcomes (N = 9) [20–22, 25, 31, 32,
34, 37, 48].
3.7 Thresholds
The thresholds to determine cost effectiveness varied in
CEAs. Of all studies assessing the cost per life-year gained
(N = 5), three studies considered a threshold between the
US$50,000 and US$100,000 [29, 40, 47], one study used a
maximum willingness-to-pay threshold of €35,000 per life-
year gained [52], and another study employed a threshold
of US$25,876 for cost effectiveness [33], which was
extrapolated from recommendations of the Commission on
Macroeconomics and Health of the World Health Organi-
zation (WHO). Other CEAs assessing the cost per addi-
tional case detected did not define a cost-effectiveness
threshold. Most of the CUAs that mentioned a cost-effec-
tiveness threshold adopted the National Institute for Health
and Care Excellence recommendations, representing a
value between £20,000 and £30,000 per QALY (N = 8)
[22, 23, 31, 44, 46, 48, 49, 51], or adopted the US rec-
ommendation of US$50,000 per QALY (N = 7) [26–28,
35, 38, 41, 46]. One study chose three different thresholds
(NZ$10,000, NZ$30,000, and NZ$50,000) [43], and
another applied the recommendation of the WHO which
indicates that an incremental cost-effectiveness ratio
(ICER) within three times the Gross Domestic Product per
capita is cost effective [45]. Three CUAs did not mention a
threshold [32, 39, 50]. As a result of the differences in
comparators, outcomes and costs considered, time horizons
and cost-effectiveness thresholds, the comparability of the
cost-effectiveness results among CEAs and CUAs is
limited.
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3.8 Sensitivity Analyses
Only deterministic sensitivity analyses were employed in
nine studies to assess the robustness of model outcomes
against parameter uncertainty and model assumptions [23,
25, 26, 30, 34, 39, 45, 48, 50]. Three studies performed
only probabilistic sensitivity analyses [42–44], and most
studies did both probabilistic and deterministic sensitivity
analyses (N = 16) [22, 27–29, 31–33, 35, 38, 40, 41, 46,
47, 49, 51, 52]. Scenario analyses were presented in seven
publications [26, 28, 29, 34, 35, 39, 41]. These analyses
mainly involved two-way sensitivity analyses, yet the study
of Kwon et al. [28] investigated the cost effectiveness and
the cost utility of BRCA mutation testing in a realistic and
an ideal scenario. Across included studies, the cost-effec-
tiveness result was most sensitive to assumptions regarding
the test accuracy and costs of the biomarker (N = 7) [22,
27, 33, 35, 38, 41, 51], the relative risk of an event (N = 4)
[31, 38, 41, 43], and the proportion of people accepting
genetic testing (N = 2) [29, 47]. One study reported that
the cost-effectiveness result was most sensitive to the dis-
count rate [52].
3.9 Handling of Specific Issues
Several economic evaluations assessed the application of
diagnostics in multiple subpopulations by either comparing
multiple scenarios or testing assumptions in deterministic
sensitivity and scenario analyses (N = 7) [36, 43, 47, 48,
50–52]. This was particularly the case in genetic cascade
testing where the number of relatives tested or the age of
patients (at the starting time of genetic testing) were varied.
Over half of the studies (N = 19) [20, 22, 24, 25, 28, 29,
33, 35, 40, 41, 43, 45–52] (Table 3) modeled multiple
realistic strategies resulting from various test sequences or
combinations of tests, with a maximum of 16 strategies
being compared with the reference strategy [47].
Other commonly reported issues in the economic eval-
uation of diagnostics were the assumptions made regarding
the compliance or acceptance of genetic testing among
relatives (N = 7) [28, 29, 44, 47, 49, 50, 52]. The robust-
ness of these assumptions was evaluated in deterministic or
probabilistic sensitivity analyses. Most of these studies
indicated that varying the compliance or acceptance rate of
testing either did not change the ICER significantly [28, 29,
50] or did improve the ICER [44, 47, 49]. The studies that
found no changes in the ICER after varying compliance
rates were CEA studies adopting a societal perspective and
assessed incremental costs per life-year gained. On the
other hand, the studies that did find improvement of the
ICER adopted a healthcare or third-party payer perspective
and assessed the incremental costs per QALY (N = 2) [44,
49]. The study of Wordsworth et al. [52] did incorporate
the acceptance rate of testing, but they did not study the
effect of changing this value on outcomes. Patient prefer-
ences were incorporated in only one study (N = 1) [31].
Table 3 Specific issues regarding the economic evaluation of diagnostics
Issue N References Solutions
Variable framing of questions due to different payer
perspectives
0
Variable framing of questions due to several clinical
perspectives
1 [46] (1) Regarding companion diagnostic; (2) regarding
therapeutic strategy
Multiple subpopulations according to test sequence
and applications in several therapeutic areas
7 [36, 43, 47, 48,
50–52]
Bivariate analyses, varied in deterministic and probabilistic
sensitivity analysis, particularly with regard to cascade
screening (number of relatives), age-targeted screening,
and multiple ethnicities
Multiple realistic strategies (computationally heavy)
due to sequences of testing and rapid evolution of
clinical pathways
19 [20, 22, 24, 25, 28,
29, 33, 35, 40, 41,
43, 45–52]
Multiple comparisons (up to N = 16) due to multiple
technologies/combinations of tests/treatment options, also
included in scenario analyses
Sensitivity of effect estimates to adherence and
compliance to a test
7 [28, 29, 44, 47, 49,
50, 52]
Proportion of compliance with diagnosis/accepting
counseling are varied in deterministic and probabilistic
sensitivity analyses or recognized by defining a reference
case scenario populated with scientific literature
Preference heterogeneity in valuing outcomes
(population versus patients)
1 [31] Incorporated as disutility in terms of ‘wait-trade-off’a
Opportunity cost of tests (depending on the number
of tests performed, geography and population
density variability)
0
Cost-sharing arrangements between producers and
payers
0
a Disutility associated with discomfort or restrictions of a diagnostic test
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This study used the ‘wait-trade-off’ method to quantify the
disutility associated with the discomfort of undergoing a
test. Incorporating the wait-trade-off did not affect the cost
effectiveness of the investigated procedure [32]. None of
the studies considered different payer perspectives, cost
sharing arrangements or variable opportunity costs due to
population density variability.
4 Discussion
Economic evaluations on biomarkers cover a wide clinical
spectrum including both markers for diagnosing or staging
a disease and markers for genetic testing to guide treat-
ment. One of the more significant findings to emerge from
this study is that the design and methodology of an eco-
nomic evaluation is and should be tailored to the diagnostic
test being evaluated, to appropriately reflect the multiple
applications of diagnostic biomarkers and to comprehen-
sively assess their added value. However, developments in
the evidence base underlying economic models and mea-
surement of outcomes beyond health are required to fully
capture the potential real-world value of diagnostic
biomarkers and hence to inform value-based payments.
This study found three methodological aspects that were
frequently employed in evaluating diagnostic biomarkers.
First, multiple diagnostic strategies were compared to
reflect the potential applications of biomarkers. The large
number of comparators resulted from the combination of
biomarkers and their relation with future treatment strate-
gies. Second, several scenarios were defined in the base-
case analyses of model-based studies to represent the rel-
evant applications in (sub)populations. The complexity of
models was particularly associated with studies assessing
genetic testing strategies, which require the evaluation of
diagnostic strategies in subpopulations depending on the
number of relatives and the age of persons being tested.
Trial-based studies were characterized by a less complex
design because they often included short time horizons,
evaluated only costs (CMA), and adopted a local per-
spective. Last, model-based studies made extensive use of
deterministic sensitivity and scenario analyses to assess the
robustness of the results regarding test acceptance and
compliance.
With regard to the cost-effectiveness results, this study
showed that the accuracy of a diagnostic test, the unit costs,
and the proportion of people (relatives) accepting genetic
testing were the driving factors of cost effectiveness. These
results are in accordance with those obtained by Frank and
Mittendorf [53], who reported the same key drivers of
uncertainty in the cost effectiveness of pharmacogenomic
profiling in metastatic colorectal cancer. Overall, the
finding of this study indicates that specific methods are
used in economic evaluations to reflect various applications
of diagnostic biomarkers.
Previous studies indicated a lack of evidence base to
populate economic models about diagnostics [54–56]. An
example is the paucity of data available about prescribing
behavior and adherence to treatment [54], which is why
assumptions have to be made. Also in this study, we saw that
sensitivity analyses were used extensively, especially with
regard to compliance and acceptance of a diagnostic test.
The poor evidence base leads to a high level of uncertainty of
the cost-effectiveness results and is a likely cause of the
limited implementation of diagnostics. Even when sup-
portive efficacy data from randomized clinical trials is
available, biomarkers are likely to be used differently in
actual practice, compared with trials or academic environ-
ments that closely follow clinical guidelines. Furthermore,
as real-world populations include multiple cohorts with
different rates of disease, biomarker prevalence and
behaviors, the population impact is likely to vary from that
estimated for hypothetical cohorts or trial participants.
Another concern regarding health economic analyses of
diagnostic biomarkers is that their potential value is not
fully captured by the conventional outcomes measures used
in economic evaluations. Beyond the outcomes on health,
diagnostic biomarkers may affect ‘personal utility’ asses-
sed by non-health outcomes [57]. This may be due to the
utility of diagnostic information (‘value of knowing’), for
example, in genetic testing of relatives, or it might result
from the experienced discomfort of undergoing a test
(process utility). However, few studies incorporated the
personal utility that is associated with the use of diagnostic
biomarkers. This finding supports the ideas of Veenstra and
Brooks [58], who stated that the role of patient-centered
value in test assessments and reimbursement policies needs
to be explored. Buchanan et al. [57] suggested that the role
of non-health outcomes in economic evaluations is still
limited because methods such as discrete choice experi-
ments are rarely used to inform economic evaluations. This
is in accordance with the results from this review seeing
only one paper that incorporated direct disutility, and the
input for this parameter was based on assumptions rather
than evidence-based methods to elicit patient preferences.
Valuing these outcomes in economic evaluations is also of
importance as it might affect adherence and thereby patient
outcomes [56]. Further research in this area is required to
provide guidance for quantifying and incorporating non-
health outcomes in economic evaluations.
A limitation of the included studies was that in many
cases the target audience was not clearly stated. A good
understanding of the target audience and perspectives is
useful to identify their evidence needs and incentives to
adopt a new technology when proven valuable [55]. Cru-
cially, the outcomes assessed in an economic evaluation
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should clearly resonate with the target audience. Cost-ef-
fectiveness outcomes from a healthcare system perspective
(public sector) or societal perspective are typically rec-
ommended for decision making, but often fail to effec-
tively inform decisions as made by specific private payers
and providers that operate in financial silos within the
healthcare system. Researchers should provide a clear
statement on who their target audience is, to substantiate
the framing of the study design. Taken together, future
research on the cost effectiveness of diagnostic biomarkers
should focus on the evidence of model input, outcomes
beyond health, and the perspective of the analysis to fully
examine the value of diagnostic biomarkers.
In the current study, a comprehensive search strategy
was used. Literature was searched in the PubMed and NHS
EED databases as it was considered as being an effective
strategy for capturing most relevant economic evaluations
on diagnostic biomarkers. As a result, some relevant pub-
lications may not have been captured. The literature was
searched on papers published from 2010 onwards to review
recent economic evaluations on diagnostic biomarkers. The
largest increase in the number of publications on diagnostic
biomarkers was observed during the last 5 years (from
2010 onwards) and was thus captured in this review. Last,
only studies published in English were included; therefore,
some potentially relevant publications may have been
missed. The scope of the review was limited to non-com-
municable diseases in middle-income and high-income
countries. Economic evaluations on diagnostic biomarkers
for communicable diseases in low-resource settings were
not reviewed in this study.
The present study contributes to the existing knowledge
about methods to examine the health economic impact of
diagnostic biomarkers. A key strength of this review was
the broad perspective on the potential use of biomarkers in
the whole spectrum of diagnostics. There was, however, a
bias towards biomarkers in cancer diagnoses as the use of
biomarkers in this field is rapidly extending [56, 59] and
overrepresented in the literature. That said, no major dif-
ferences between study design and outcomes were
observed between disease groups.
5 Conclusions
Published health economic evaluations of biomarkers used for
diagnosing and staging diseases are characterized by a large
number of comparators and potential clinical applications,
which need to be modeled in order to determine the
biomarkers’ value. Improving the evidence base of and
methods for incorporating non-health outcomes and patient
preferences is crucial to fully capture the value of diagnostic
biomarkers, and to inform value-based reimbursements.
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Appendix
Search Strategies
For an overview of the search strategies used in PubMed
and NHS EED databases, see Tables 4 and 5.




#3. clinical laboratory techniques/economics[MeSH]
#4. tumor markers, biological/economics[MeSH]
#5. #1 OR #2 OR #3 OR #4
#6. diagnos*[Title/Abstract]
#7. cost$effective$[Title/Abstract]
#8. ‘‘Cost Benefit Analysis’’[MeSH]
#9. #7 OR #8
#10. #5 AND #6 AND #9
#11. Limit to: human subjects, year of publication C2010, English,
free-full text
Mesh Medical Subject Headings, */$ wildcard characters
Table 5 Search strategy NHS EED
# Search term
#1. biomarker
#2. MeSH biological markers/economics EXPLODE ALL TREES
#3. MeSH clinical laboratory techniques/economics EXPLODE
ALL TREES
#4. MeSH tumor markers, biological/economics EXPLODE ALL
TREES
#5. #1 OR #2 OR #3 OR #4
#6. diagnos*
#7. #5 AND #6
NHS EED National Health Service Economic Evaluation Database, */
$ wildcard characters
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